256 related articles for article (PubMed ID: 26818417)
1. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials.
Shah ED; Siegel CA; Chong K; Melmed GY
Inflamm Bowel Dis; 2016 Apr; 22(4):933-9. PubMed ID: 26818417
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
Moćko P; Kawalec P; Pilc A
Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
[TBL] [Abstract][Full Text] [Related]
4. Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability.
Shah ED; Siegel CA; Chong K; Melmed GY
Dig Dis Sci; 2015 Aug; 60(8):2408-18. PubMed ID: 25772778
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
[TBL] [Abstract][Full Text] [Related]
7. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 May; 45(10):1291-1302. PubMed ID: 28326566
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
[TBL] [Abstract][Full Text] [Related]
11. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis.
Mosli MH; MacDonald JK; Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; Khanna R; Feagan BG
Inflamm Bowel Dis; 2015 May; 21(5):1151-9. PubMed ID: 25844963
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis.
Chu X; Biao Y; Liu C; Zhang Y; Liu C; Ma JZ; Guo Y; Gu Y
BMC Gastroenterol; 2023 Oct; 23(1):346. PubMed ID: 37803294
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis.
Nikfar S; Ehteshami-Ashar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Dec; 32(14):2304-15. PubMed ID: 21353102
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of clinical remission with biologics and small molecules in inflammatory bowel disease according to trial design: Meta-analysis.
Barberio B; Gracie DJ; Black CJ; Ford AC
Dig Liver Dis; 2024 Jan; 56(1):7-14. PubMed ID: 37357037
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
[TBL] [Abstract][Full Text] [Related]
18. A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease.
Yang Z; Ye X; Wu Q; Wu K; Fan D
Int J Surg; 2014; 12(5):516-22. PubMed ID: 24576593
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis.
Nishida Y; Hosomi S; Yamagami H; Sugita N; Itani S; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Kakimoto K; Tanigawa T; Watanabe T; Fujiwara Y
Intern Med; 2019 Aug; 58(16):2305-2313. PubMed ID: 31118391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
